In March of 2024 U CAN-CER-VIVE Foundation awarded Suresh Balasubramanian, M.D., and his team of investigators a $405,315 grant for their continued research, titled “Biological Aging and Mutational/Immunological Signatures as Prognostic and Predictive Biomarkers for Treatment of Hematological Malignancies.”
“Receiving such generous backing from the U CAN-CER VIVE foundation is truly significant. Their consistent support for Michigan Researchers over the past several years has been instrumental in advancing scientific research,” said Dr. Balasubramanian. “This grant will enable us to employ the latest scientific techniques to finetune and validate a new biomarker in different clinical settings, which has the potential to transform the care of our patients.”
Dr. Balasubramanian is a hematologist and medical oncologist specializing in the treatment of clonal hematopoiesis, myelodysplasia, leukemia, lymphoma, and multiple myeloma. He’s also a member of the Hematology Oncology and Multiple Myeloma and Amyloidosis Multidisciplinary Teams, and the Molecular Therapeutics (MT) Research Program at Karmanos. He and his team of investigators are exploring the idea of estimating biological age as a better surrogate to determine treatment decisions for certain cancers as opposed to chronological age. Chronological age takes into the number of birthdays a patient has, whereas biological age would help consider various changes that happen in a patient’s body at the tiny level of cells and their parts.
U CAN-CER VIVE is grateful to support cancer research here in Michigan. As a nonprofit that is 100% volunteer based, we are proud to donate 100% of profits raised directly to our cause. Our goal? A CANCER FREE WORLD. Click below to continue reading and to learn more about how our research dollars are in action at Barbara Ann Karmanos Cancer Institute right here in Detroit, Michigan.
